HGH Fragment 176-191 Dosing Protocol: Lipolytic Domain vs. AOD-9604
Also known as: Frag 176-191, hGH(176-191) Lipolytic Peptide, Fragment 176-191 vs. AOD-9604
Studied in published research — not a medical recommendation. Primary protocol (Fasted Lipolytic SubQ Protocol): 250 mcg – 500 mcg (0.25–0.5 mg), 1–2x daily strictly fasted (AM before fasted cardio, optional PM 3+ hrs post-meal).
1–2x daily strictly fasted (AM before fasted cardio, optional PM 3+ hrs post-meal)
Research-reported range; the linked study used a different dose or units. Must be administered in a low-insulin fasted state; elevated post-meal insulin blunts hormone-sensitive lipase activation
Subcutaneous injection (abdominal adipose)
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 20 doses in the vial at the low end (10 doses at the high end).
Save HGH Fragment 176-191 to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Peptide?
A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.
Bottom Line Up Front
HGH Fragment 176-191 is the synthetic 16-AA C-terminal lipolytic domain of human growth hormone. It stimulates adipocyte beta-3 adrenergic receptors and hormone-sensitive lipase (HSL) without binding the full-length GH receptor, raising IGF-1, or inducing insulin resistance (unlike 17-AA Tyr-modified AOD-9604, it has no added N-terminal tyrosine).
Fasted lipolysis and anti-lipogenic signaling without IGF-1 or blood glucose elevation
Central appetite suppression (zero satiety effect; requires fasted dosing and caloric control)
None
3 (0 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. HGH Fragment 176-191 is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
While full-length 191-AA somatropin (hGH) stimulates both anabolic IGF-1 production (via residues 1–175) and adipose lipolysis (via the C-terminal disulfide loop at residues 176–191), exogenous hGH can induce insulin resistance and fluid retention. Monash University biochemists discovered that cleaving only residues 176–191 preserves 100% of the hormone’s lipolytic and anti-lipogenic signaling in white adipose tissue while completely eliminating GH receptor binding, IGF-1 elevation, and diabetogenic insulin antagonism.
Mechanisms of Action
- Up-regulates adipocyte beta-3 adrenergic receptor (β3-AR) expression and hormone-sensitive lipase (HSL) activity to mobilize stored triglycerides
- Inhibits acetyl-CoA carboxylase to suppress de novo lipogenesis (fatty acid synthesis) in white adipose tissue
- Zero binding to the full-length transmembrane Growth Hormone Receptor (GHR) and zero effect on serum IGF-1 levels
- Does not induce hyperinsulinemia or impaired glucose tolerance—unlike exogenous full-length hGH
Common Ratios, Vial Formats & Dosing Breakdown
Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.
HGH Fragment 176-191 (16-AA) vs. AOD-9604 (17-AA Tyr-Stabilized)
5 mg or 10 mg Lyophilized Vial
250–500 mcg SubQ fasted AM (30–60 min before fasted cardio/meal)
Why this ratio: Fragment 176-191 is the exact native 16-AA hGH(176-191) sequence and dissolves cleanly in standard BAC water; AOD-9604 adds an N-terminal Tyrosine (Tyr-hGH 177-191) and often requires pH-adjusted or acetic-acid-buffered reconstitution to prevent gelling.
Research Protocols
Summaries of published research. For educational purposes only.
Metabolic, Hepatic & Incretin Safety Biomarker Panel (HGH Fragment 176-191)
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Related Studies
Demonstrated that the C-terminal 176-191/177-191 domain of human growth hormone selectively reduces body fat accumulation and enhances fat oxidation in obese animal models without altering blood glucose or IGF-1.
Limitations: Human obesity trials conducted with the Tyr-modified analog (AOD-9604) showed modest standalone weight loss compared to modern GLP-1 agonists.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Must be administered strictly fasted (at least 2–3 hours after and 45–60 minutes before carbohydrates/insulin spikes) or lipolytic signaling is blunted
- •Prohibited at all times in tested sports by WADA under Section S2.2 (GH fragments)
- •Not FDA approved; removed from FDA 503A Category 2 compounding list—available as an analytical research reference standard
Where to get HGH Fragment 176-191, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More metabolic peptides
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the horm...
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It rep...
Retatrutide
Retatrutide is a triple hormone receptor agonist developed b...
Liraglutide
Liraglutide is an FDA-approved GLP-1 receptor agonist used f...
AOD-9604 (hGH Frag 176-191)
AOD-9604 is a modified fragment of human growth hormone (hGH...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.